Oppenheimer Sticks to Their Hold Rating for Irhythm Technologies (IRTC)

In a report released today, Suraj Kalia from Oppenheimer maintained a Hold rating on Irhythm Technologies (IRTCResearch Report). The company’s shares closed last Monday at $74.18, close to its 52-week low of $70.35.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 6.9% and a 54.3% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.

Irhythm Technologies has an analyst consensus of Hold, with a price target consensus of $97.80, representing a 23.4% upside. In a report issued on May 7, Needham also assigned a Hold rating to the stock.

See today’s analyst top recommended stocks >>

Based on Irhythm Technologies’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $74.31 million and GAAP net loss of $27.78 million. In comparison, last year the company earned revenue of $63.54 million and had a GAAP net loss of $9.07 million.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IRTC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.